Paradigm Biopharmaceuticals Limited (ASX: PAR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Paradigm Biopharmaceuticals Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Paradigm Biopharmaceuticals Limited (ASX: PAR)
Latest News
Healthcare Shares
Why did this ASX biotech stock explode 52% higher on Monday?
Healthcare Shares
2 All Ords ASX healthcare shares making BIG moves on quarterly updates
Healthcare Shares
Guess which ASX biotech stock is surging 11% on big FDA news
Healthcare Shares
Bell Potter says this ASX biotech stock could rocket 80%
Healthcare Shares
3 ASX healthcare shares outperforming on quarterly updates
Share Gainers
Why Fiducian Group, Northern Star, Paradigm, and Santos shares are charging higher
Healthcare Shares
Here's a 33c ASX stock that could have the potential to reach $1+
Share Fallers
Why Core Lithium, New Hope, Paradigm, and Sayona Mining shares are sinking today
52-Week Lows
Guess which ASX All Ords share is crashing 34% to a 52-week low
Healthcare Shares
3 ASX healthcare shares up 10% to 22% on news
Healthcare Shares
Guess which ASX healthcare share is rocketing 18% today
Share Fallers
Why Latin Resources, Paradigm, Sunland, and Weebit Nano shares are falling
Frequently Asked Questions
-
No, Paradigm does not pay shareholder dividends at this time.
-
Paradigm Biopharmaceuticals Limited listed on the ASX on 19 August 2015.
PAR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Ltd (ASX: PAR) is a late-stage drug development company researching drug repurposing. The company seeks to identify and transform existing molecules to develop effective treatments for conditions with limited treatment options. Currently, more than 30% of therapies approved or launched globally represent drugs approved for new indications, reformulations, or new combinations of existing drugs.
Paradigm's current commercial prospect is injectable pentosan polysulfate sodium (PPS, or brand name Zilosul®) in the treatment of osteoarthritis. PPS is FDA-approved and has a track record of treating inflammation including bladder condition cystitis and is used in the EU for preventing deep vein thrombosis. Paradigm has advanced to Phase 3 trial stage investigating PPS for osteoarthritis treatment. The company is based in Melbourne with offices in the US and Europe.
